Thymalin
Aliases: Thymulin-like peptide complex · Timalin
Last verified: 2026-09-23
The short version
A polypeptide extract of bovine thymus — a Russian bioregulator approved for immunodeficiencies. Used in gerontology for immunomodulation and "rejuvenation" of the immune system. Key fact: Russian studies: reduced mortality and improved immune parameters in the elderly in long-term observational series (Khavinson).
Identity & type
- Molecular type
- bioregulator
- Origin
- A polypeptide extract of bovine thymus — a Russian bioregulator approved for immunodeficiencies.
Mechanism of action
A complex of thymic peptides regulating T-lymphocyte differentiation and Th1/Th2 balance; related to the peptide thymulin (Zn-dependent).
not confirmed in humans
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. 10 mg IM daily for 3–10 days per course; geroprotective protocols use 1–2 courses yearly.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
10 mg IM daily for 3–10 days per course; geroprotective protocols use 1–2 courses yearly. Fewer infections and better immune response during the season are reported; older users describe improved energy. All based on Russian experience.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Fewer infections and better immune response during the season are reported; older users describe improved energy. All based on Russian experience.
Protocol — official vs community
Official / label
Russian-approved thymic preparation; course-based geriatric/immunomodulatory use per domestic labeling.
- 01Course-based per domestic labeling
Duration: Course-based.
Thymic peptides have the most plausible mechanistic story in the bioregulator class (immune aging is real), and the same replication problem.
Community (anecdotal)
5–10 mg SC daily for 10–20 days.
- Cycle:
- 1–2× per year, often with epitalon/pinealon.
- Break:
- Months between courses.
Commonly positioned as the 'immune' third of the longevity bioregulator trio.
Human evidence
Russian studies: reduced mortality and improved immune parameters in the elderly in long-term observational series (Khavinson).
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Rare allergic reactions; contraindicated in severe hypersensitivity.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics